Literature DB >> 19072374

Specific considerations in the treatment of pediatric inflammatory bowel disease.

Andrew B Grossman1, Robert N Baldassano.   

Abstract

Inflammatory bowel disease is one of the most prevalent chronic inflammatory disorders and commonly presents during childhood or adolescence. Occurring during a critical period of growth and development, pediatric Crohn's disease and ulcerative colitis require special consideration. Children often experience growth failure, malnutrition, pubertal delay and bone demineralization. Medical treatment must be optimized to promote clinical improvement and reverse growth failure with minimal toxicity. In addition to pharmacologic and surgical interventions, nutritional therapies play a vital role in the management of pediatric inflammatory bowel disease. This review will outline the epidemiology and clinical complications that are unique to pediatric inflammatory bowel disease, current trends, and recent advances in nutritional and pharmacologic treatment, and projected future therapeutic direction.

Entities:  

Mesh:

Year:  2008        PMID: 19072374     DOI: 10.1586/17474124.2.1.105

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  3 in total

1.  Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way?

Authors:  Rebekka Mueller; Farah Ziade; Valérie Pittet; Nicolas Fournier; Jessica Ezri; Alain Schoepfer; Susanne Schibli; Johannes Spalinger; Christian Braegger; Andreas Nydegger
Journal:  J Crohns Colitis       Date:  2015-10-29       Impact factor: 9.071

2.  Short- and long-term efficacy of endoscopic balloon dilation in Crohn's disease strictures.

Authors:  Nicola de'Angelis; Maria Clotilde Carra; Osvaldo Borrelli; Barbara Bizzarri; Francesca Vincenzi; Fabiola Fornaroli; Giuseppina De Caro; Gian Luigi de'Angelis
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

3.  Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses.

Authors:  Rongli Zhang; Shila Gilbert; Xinsheng Yao; Jefferson Vallance; Kris Steinbrecher; Richard Moriggl; Dongsheng Zhang; Madhu Eluri; Haifeng Chen; Huiqing Cao; Noah Shroyer; Lee Denson; Xiaonan Han
Journal:  Pharmacol Res Perspect       Date:  2015-02-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.